Malignancies in HIV: Pre- and post-highly active antiretroviral therapy

Journal of the National Medical Association

Volumn 100, Issue 7, 2008, Pages 817-820

  Nutankalva, Lavanya ^a   Wutoh, Anthony K ^b   McNeil, John ^a   Frederick, Winston R ^a   Reddy, Ramani B ^a   Daftary, Monika ^b   Gentles, Andrew ^b   Addae Afoakwa, Kwame ^b  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

Cancer; HIV AIDS; Kaposi's sarcoma; Lung

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ANUS CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM TUMOR; COHORT ANALYSIS; ETHNIC GROUP; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

EID: 47749139720     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31375-4     Document Type: Article

References (11)

1. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006; 368(9534):451-458.
2. Bartlett J, Gallant J. (2004, May). 2004 Medical Management of HIV infection. John Hopkins University Medicine Health Publishing Business Group.
3. Engels E, Pfeiffer R, Goedert J, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20(12):1645-1654.
4. Centers for Disease Control. Update on acquired immune deficiency syndrome (AIDS)-United States. MMWR Morb Mortal Wkly Rep. 1987;36:1S-15S.
5. Centers for Disease Control. 1993 revised classification for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:961-962.
6. Aoki Y, Yarchoan R, Braun J, et al. Viral and cellular cytokines in AIDS related malignant lymphomatous effusions. Blood. 2000;96:1599-1601.
7. Yarchoan R, Tosato G, Little RF. Therapy Insight: AIDS-Related Malignancies-The Influence of Antiviral Therapy on Pathogenesis and Management. Nat Clin Pract Oncol. 2005;2:406-415.
8. Aoki Y and Tosato G. HIV-1 Tat enhances Kaposi's sarcoma-associated herpesvirus (KSHV) infectivity. Blood. 2004;104:810-814.
9. Bedimo R, Chen R, Accortt N et al. Trends in AIDS-defining and Non-AIDS defining malignancies among HIV-infected patients. 1989-2002. Clin Infect Dis. 2004;39:1380-1384.
10. Mbulaiteye S, Katabira E, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer. 2006;118(4):985-990.
11. Rabkin CS. AIDS and cancer in the era of highly active antiretroviral therapy (HAART). Eur J Cancer. 2001;37:1316-1319.